Lower sales offset by margins as operational measures take effect. EPS estimates largely intact due to lower opex and interest expenses. Full effect of op. improvements yet to be seen, but focus turns to M&A.
Expect strong Q4 sales after order intake surprise in Q3. Estimates unchanged, growth and margin expansion in '24e-'25e. Trading at 12-10x P/E, reiterate fair value range of SEK 35-45.
Another strong quarter, order intake up 33%, EBITA margin 9.8%. Marks the fourth quarter in a row with profitability improvements. Long-term EBITA margin up to 8% (7%), fair value up to SEK 35-45.
Q3e sales SEK 221m, up 11%, adj. EBITA margin 7.2% (8.7%). Growth to slow as book-to-bill normalises, profitability outlook good. Fair value SEK 30-40, trading at 12-11x P/E vs. peers at 23-11x.
Decentralised, diversified B2B distribution and original product group. New management aims to boost profitability, promising signs in H1'23. '23e-'25e adj. P/E of 12-10x, fair value SEK 30-40.
Another good quarter, 15% org. growth and 7.1% EBITA margin. Order intake still high, up 9% despite tough comps; outlook good. Share still trading below peers despite promising developments.
Q1: 31% organic sales growth and EBITA margin doubling. We raise estimates on further signs of profitability progress. Valuation still below peers despite margin prospects.
Q1e: SEK 190m sales, +4.7% y-o-y; 6.5m EBITA, 3.4% margin. Minor estimate changes; reiterate fair value range of SEK 30-40. Trading at 12-9x '23e-'25e P/E vs. peer median of 28-11x.